|
|
125742_S1_M1_356h.pdf
|
PDF
|
714.46 KB
|
|
|
125742_S1_M1_3674.pdf
|
PDF
|
5.12 MB
|
|
|
125742_S1_M1_cover.pdf
|
PDF
|
1.32 MB
|
|
|
125742_S1_M1_debarment.pdf
|
PDF
|
656.42 KB
|
|
|
125742_S1_M1_exclusivity-claim.pdf
|
PDF
|
616.11 KB
|
|
|
125742_S1_M1_fast-track-designation.pdf
|
PDF
|
649.42 KB
|
|
|
125742_S1_M1_financial-cert-3454.pdf
|
PDF
|
3.44 MB
|
|
|
125742_S1_M1_financial-cert-bias.pdf
|
PDF
|
695.81 KB
|
|
|
125742_S1_M1_ipsp-agreed-letter.pdf
|
PDF
|
657.84 KB
|
|
|
125742_S1_M1_priority-review-request.pdf
|
PDF
|
1.59 MB
|
|
|
125742_S1_M1_trans-of-oblig.pdf
|
PDF
|
717.14 KB
|
|
|
125742_S1_M1_us-agent-authorization.pdf
|
PDF
|
1.03 MB
|
|
|
125742_S1_M1_userfee.pdf
|
PDF
|
627.8 KB
|
|
|
125742_S1_M1_waiver-req-designated-suffix.pdf
|
PDF
|
2.74 MB
|
|
|
125742_S1_M2_22_introduction.pdf
|
PDF
|
670.17 KB
|
|
|
125742_S1_M2_24_nonclinical-overview.pdf
|
PDF
|
1.61 MB
|
|
|
125742_S1_M2_26_pharmkin-tabulated-summary.pdf
|
PDF
|
1.34 MB
|
|
|
125742_S1_M2_26_pharmkin-written-summary.pdf
|
PDF
|
1.43 MB
|
|
|
125742_S1_M2_27_literature-references.pdf
|
PDF
|
1.75 MB
|
|
|
125742_S1_M2_27_synopses-indiv-studies.pdf
|
PDF
|
1.75 MB
|
|
|
125742_S1_M4_4223_185350.pdf
|
PDF
|
1.4 MB
|
|
|
125742_S1_M4_4223_R-20-0072.pdf
|
PDF
|
5.21 MB
|
|
|
125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf
|
PDF
|
889.15 KB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf
|
PDF
|
1.26 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf
|
PDF
|
2.04 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf
|
PDF
|
2.39 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-errata.pdf
|
PDF
|
2.27 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf
|
PDF
|
15.7 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf
|
PDF
|
1.81 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf
|
PDF
|
4.78 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf
|
PDF
|
12.02 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf
|
PDF
|
2.29 MB
|
|
|
125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf
|
PDF
|
31.31 MB
|
|
|
125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf
|
PDF
|
13 MB
|
|
|
125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf
|
PDF
|
36.94 MB
|
|
|
125742_S1_M5_CRF_c4591001-1085-10851018.pdf
|
PDF
|
2.25 MB
|
|
|
125742_S1_M5_CRF_c4591001-1085-10851116.pdf
|
PDF
|
1.19 MB
|
|
|
125742_S1_M5_CRF_c4591001-1085-10851129.pdf
|
PDF
|
1.94 MB
|
|
|
125742_S1_M5_CRF_c4591001-1085-10851216.pdf
|
PDF
|
1.22 MB
|
|
|
125742_S1_M5_CRF_c4591001-1085-10851246.pdf
|
PDF
|
1.14 MB
|
|
|
125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf
|
PDF
|
602.23 KB
|
|
|
125742_S1_M5_c4591001-A-adrg.pdf
|
PDF
|
1.54 MB
|
|
|
125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf
|
PDF
|
627.05 KB
|
|
|
125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf
|
PDF
|
634.25 KB
|
|
|
125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf
|
PDF
|
620.2 KB
|
|
|
125742_S1_M5_c4591001-A-comorbidity-categories.pdf
|
PDF
|
636.9 KB
|
|
|
125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf
|
PDF
|
606.89 KB
|
|
|
125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf
|
PDF
|
846.03 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf
|
PDF
|
629.08 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf
|
PDF
|
670.23 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf
|
PDF
|
631.62 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-chf.pdf
|
PDF
|
628.18 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-dementia.pdf
|
PDF
|
625.82 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf
|
PDF
|
625.67 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf
|
PDF
|
626.79 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf
|
PDF
|
625.58 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-leukemia.pdf
|
PDF
|
631.44 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf
|
PDF
|
640.12 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf
|
PDF
|
635.64 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-mi.pdf
|
PDF
|
624.25 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf
|
PDF
|
628.36 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf
|
PDF
|
625.68 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf
|
PDF
|
624.81 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf
|
PDF
|
631.6 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf
|
PDF
|
629.63 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-renal.pdf
|
PDF
|
628.94 KB
|
|
|
125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf
|
PDF
|
629.4 KB
|
|
|
125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf
|
PDF
|
2.22 MB
|
|
|
125742_S1_M5_c4591001-T-S-roadmap.pdf
|
PDF
|
702.77 KB
|
|
|
125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf
|
PDF
|
666.79 KB
|
|
|
125742_S1_M5_c4591001-T-S-suppl-arg.pdf
|
PDF
|
738.13 KB
|
|
|
125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf
|
PDF
|
17.43 MB
|
|
|
FDA-CBER-2021-5683-0021888 to -0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt
|
TXT
|
13.87 KB
|
|
|
FDA-CBER-2021-5683-0021902 to -0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt
|
TXT
|
14.67 KB
|
|
|
FDA-CBER-2021-5683-0021916 to -0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt
|
TXT
|
14.75 KB
|
|
|
FDA-CBER-2021-5683-0021930 to -0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt
|
TXT
|
15.11 KB
|
|
|
FDA-CBER-2021-5683-0021944 to -0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt
|
TXT
|
35.46 KB
|
|
|
FDA-CBER-2021-5683-0021964 to -0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt
|
TXT
|
17.94 KB
|
|
|
FDA-CBER-2021-5683-0021981 to -0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt
|
TXT
|
81.06 KB
|
|
|
FDA-CBER-2021-5683-0022028 to -0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt
|
TXT
|
19.55 KB
|
|
|
FDA-CBER-2021-5683-0022041 to -0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt
|
TXT
|
19.46 KB
|
|
|
FDA-CBER-2021-5683-0022054 to -0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt
|
TXT
|
12.27 KB
|
|
|
FDA-CBER-2021-5683-0022063 to -0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt
|
TXT
|
71.56 KB
|
|
|
FDA-CBER-2021-5683-0022136 to -0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt
|
TXT
|
192.86 KB
|
|
|
FDA-CBER-2021-5683-0022326 to -0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt
|
TXT
|
27.11 KB
|
|
|
FDA-CBER-2021-5683-0022346 to -0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt
|
TXT
|
32.19 KB
|
|
|
FDA-CBER-2021-5683-0022365 to -0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt
|
TXT
|
155.76 KB
|
|
|
FDA-CBER-2021-5683-0022561 to -0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt
|
TXT
|
11.04 KB
|
|
|
FDA-CBER-2021-5683-0022568 to -0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt
|
TXT
|
48.94 KB
|
|
|
FDA-CBER-2021-5683-0022601 to -0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt
|
TXT
|
24.03 KB
|
|
|
FDA-CBER-2021-5683-0022618 to -0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt
|
TXT
|
74.64 KB
|
|
|
FDA-CBER-2021-5683-0022692 to -0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt
|
TXT
|
74.71 KB
|
|
|
FDA-CBER-2021-5683-0022766 to -0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt
|
TXT
|
29.2 KB
|
|
|
FDA-CBER-2021-5683-0022793 to -0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt
|
TXT
|
75.39 KB
|
|
|
FDA-CBER-2021-5683-0022867 to -0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt
|
TXT
|
197.17 KB
|
|
|
FDA-CBER-2021-5683-0023007 to -0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt
|
TXT
|
43.24 KB
|
|
|
FDA-CBER-2021-5683-0023032 to -0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt
|
TXT
|
44.8 KB
|
|
|
FDA-CBER-2021-5683-0023150 to -0023454_125742_S1_M5_c4591001-A-define.xml
|
XML
|
1.37 MB
|
|
|
FDA-CBER-2021-5683-0023455 to -0023486_125742_S1_M5_c4591001-A-define-2-0-0.xsl
|
XSL
|
183.26 KB
|
|
|
FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx
|
XLSX
|
12.98 KB
|
|
|
FDA-CBER-2021-5683-0023500 to -0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx
|
XLSX
|
28.74 KB
|
|
|
FDA-CBER-2021-5683-0023523 to -0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx
|
XLSX
|
18.48 KB
|
|
|
FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx
|
XLSX
|
18.86 KB
|
|
|
FDA-CBER-2021-5683-0023550 to -0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx
|
XLSX
|
22.28 KB
|
|
|
FDA-CBER-2021-5683-0023711 to -0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx
|
XLSX
|
84.13 KB
|
|
|
FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx
|
XLSX
|
22.73 KB
|
|
|
FDA-CBER-2021-5683-0023895 to -0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx
|
XLSX
|
34.78 KB
|
|
|
FDA-CBER-2021-5683-0023919 to -0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx
|
XLSX
|
12.44 KB
|
|
|
FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx
|
XLSX
|
10.25 KB
|
|
|
FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx
|
XLSX
|
9.44 KB
|
|
|
FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx
|
XLSX
|
9.2 KB
|
|
|
FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx
|
XLSX
|
9.77 KB
|
|
|
FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx
|
XLSX
|
9.58 KB
|
|
|
FDA-CBER-2021-5683-0023936 to -0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx
|
XLSX
|
11.67 KB
|
|
|
FDA-CBER-2021-5683-0023944 to -0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx
|
XLSX
|
17.02 KB
|
|
|
FDA-CBER-2021-5683-0023955 to -0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx
|
XLSX
|
14.32 KB
|
|
|
FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx
|
XLSX
|
8.9 KB
|
|
|
FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx
|
XLSX
|
10.35 KB
|
|
|
FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx
|
XLSX
|
9.2 KB
|
|
|
FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx
|
XLSX
|
9.15 KB
|
|
|
FDA-CBER-2021-5683-0023971 to -0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx
|
XLSX
|
11.71 KB
|
|
|
FDA-CBER-2021-5683-0023975 to -0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx
|
XLSX
|
11.55 KB
|
|
|
FDA-CBER-2021-5683-0023979 to -0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx
|
XLSX
|
11.09 KB
|
|
|
FDA-CBER-2021-5683-0023983 to -0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx
|
XLSX
|
23.94 KB
|
|
|
FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx
|
XLSX
|
21.34 KB
|